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Abstract
Background: Bloodstream infections (BSIs) are the major cause of mortality in cancer patients. Molecular techniques
are used for rapid diagnosis of BSI, allowing early therapy and improving survival. We aimed to establish whether real-
time quantitative polymerase chain reaction (qPCR) could improve early diagnosis and therapy in paediatric cancer
patients, and describe the predominant pathogens of BSI and their antimicrobial susceptibility.
Methods: Blood samples were processed by the BACTEC system and microbial identification and susceptibility tests
were performed by the Phoenix system. All samples were screened by multiplex 16 s rDNA qPCR. Seventeen species
were evaluated using sex-specific TaqMan probes and resistance genes blaSHV, blaTEM, blaCTX, blaKPC, blaIMP,
blaSPM, blaVIM, vanA, vanB and mecA were screened by SYBR Green reactions. Therapeutic efficacy was evaluated at
the time of positive blood culture and at final phenotypic identification and antimicrobial susceptibility results.
Results: We analyzed 69 episodes of BSI from 64 patients. Gram-positive bacteria were identified in 61 % of the
samples, Gram-negative bacteria in 32 % and fungi in 7 %. There was 78.2 % of agreement between the phenotypic
and molecular methods in final species identification. The mecA gene was detected in 81.4 % of Staphylococcus spp.,
and 91.6 % were concordant with the phenotypic method. Detection of vanA gene was 100 % concordant. The
concordance for Gram-negative susceptibilities was 71.4 % for Enterobacteriaceae and 50 % for Pseudomonas
aeruginosa. Therapy was more frequently inadequate in patients who died, and the molecular test was concordant
with the phenotypic susceptibility test in 50 %.
Conclusions: qPCR has potential indication for early identification of pathogens and antimicrobial resistance genes
from BSI in paediatric cancer patients and may improve antimicrobial therapy.
Abbreviations: AML, Acute myeloid leukaemia; BC, Blood culture; BSI, Bloodstream infection; CoNS, Coagulase-
negative Staphylococcus; CVC, Central venous catheter; ESBL, Extended spectrum β-lactamase; FN, Febrile neutropenia;
ICU, Intensive care unit; MIC, Minimum inhibitory concentration; qPCR, quantitative polymerase chain reaction;
VRE, Vancomycin-resistant enterococcus
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Background
Chemotherapy for childhood cancer is one of the great-
est successes of modern medicine and the overall sur-
vival is now over 70 %. However myelossupression is a
consequence of virtually all chemotherapy regimens and
profound neutropenia (<0,5 × 109) is a major risk factor
for overwhelming infections [1].
The relative frequency of different organisms causing
bacterial infection may vary with time period and geo-
graphical location. Regardless of these variations in
causative organism, and the widespread use and avail-
ability of powerful antibiotics, bacteremia/sepsis remains
the most important independent prognostic marker for
mortality in children with cancer who have febrile neu-
tropenia. A diagnosis of sepsis or bacteremia increased
in 10-fold increase risk of death [2].
In 40 % of children that have clinical diagnosis of
sepsis and 75 % of those with high-risk FN, the microor-
ganisms cannot be detected by currently available conven-
tional microbiological techniques [3]. Early empirical
treatment of fever in cancer patients remains the standard
of care for the management of febrile neutropenia (FN).
In this context, our group developed an in-house, real-
time, quantitative polymerase chain reaction (qPCR) dir-
ectly from BACTEC blood culture (BC) bottles to iden-
tify the main pathogens and important resistance genes
causing bloodstream infection (BSI) [4]. The aim of this
study was to evaluate if this technique could anticipate
and improve the diagnosis and therapy in paediatric
cancer patients. The secondary objective was to describe




Prospective study between March 2011 and March 2012
at the Institute of Paediatric Oncology, São Paulo, Brazil.
Informed consent was obtained from all patients and the
study was approved by the Clinical Research Ethics
Committee of the Federal University of São Paulo. The
samples were collected as part of standard care from pa-
tients suspected of BSI in the hospital. BSI was defined
as the isolation of a bacterial or fungal pathogen from at
least one BC.
All episodes of BSI were sub-classified as single agent
(Gram-positive bacteria, Gram-negative bacteria, or
fungi) or polymicrobial if two or more pathogens were
isolated from a single BC.
We included only the BSI episodes for which BACTEC
bottles were available for molecular tests without selec-
tion. We excluded polymicrobial episodes because it is
not feasible to compare the conventional method with
the molecular method if more than one agent grows in
the same BC.
Data collection
Clinical data and bloodstream isolates were prospectively
collected by local infection control practitioners.
Definitions
Neutropenia was defined as an absolute neutrophil
count of <500 cells/mm3 within 48 h after onset of bac-
teraemia [5]. Sepsis was defined as systemic inflamma-
tory response syndrome in the presence of suspected or
proven infection and organ dysfunction, according to
international consensus guidelines. Septic shock was de-
fined as sepsis with systolic blood pressure <90 mmHg
that did not respond to adequate fluid resuscitation, and
necessitated the use of a vasopressor. Severe sepsis was
defined as inflammatory response syndrome triggered by
a microorganism, identified or not, plus one of the fol-
lowing: cardiovascular organ dysfunction or acute re-
spiratory distress syndrome; or dysfunction of two or
more other organs: neurological, renal or hepatic [6].
Patients without any identifiable source of infection
were classified as primary bacteraemia. Secondary BSIs
were regarded as those with a clear source of bacter-
aemia other than a central line. Sources of secondary
BSI were identified by culture of samples obtained from
distant sites that yielded the same pathogen with an
identical resistance pattern. Distant sites were sites other
than a central line where an infection was diagnosed
(e.g. pneumonia, urinary tract infection or abdominal in-
fection). Intensive care unit (ICU) stay was defined as
current stay in the ICU at onset of bacteraemia, regard-
less of previous history of ICU admission.
Empirical antimicrobial therapy was instituted accord-
ing to the standard protocol of the institution [7] at the
time of fever and suspicion of BSI after collection of
blood culture. Antimicrobial therapy was analysed in
two periods: Period 1: antibiotics in use when the Gram
stain test of a positive bloodstream culture was available
to the physician; and Period 2: antibiotics in use when
the final results of microbial identification and anti-
microbial susceptibility test were reported to the phys-
ician. Antimicrobial therapy was considered adequate if
the treatment regimen included one or more antibiotics
active in vitro against the microorganism identified by
phenotypic tests.
Mortality associated with infection was defined as
death within 14 days of bacteraemia and there was no
other explanation for that.
Microbiological features
BCs were performed using the BACTEC 9240 instru-
ment (Becton & Dickinson, Microbiology Systems,
Cockeysville, MD, USA). Identification at the species
level and susceptibility testing were performed using the
automated system Phoenix 100 (Becton & Dickinson
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Microbiology Systems). Minimum inhibitory concentra-
tion (MIC) determination was done by E test (AB Biodisk,
Sweden) for oxacillin and carbapenems and by agar dilu-
tion for vancomycin, to confirm resistant phenotypes.
Molecular detection of microorganisms and resistance
genes
Total DNA was extracted from 500 μL of positive or
negative BC broth after incubation on BACTEC 9240,
using the phenol–chloroform method (Brazol; LGC
Biotechnologia, Cotia, Brazil) with 300-mg glass beads
(0.3-mm diameter; Scientific Industries, Bohemia, NY,
USA) and processed in a disruptor Genie (Scientific
Industries) for 10 min to achieve cell lysis [4].
Real-time qPCR was performed as follows according
to the protocols published by Menezes et al. in 2013 [4, 8].
Taqman-based multiplex detection of 16S rDNA gene
with Gram-positive- and Gram-negative-specific probes;
single SYBR green detection of each following resistance
genes blaSHV, blaTEM, blaCTX-M, blaIMP, blaSPM, blaGIM,
blaSIM blaVIM, blaKPC, vanA, vanB and mecA; and single
Taqman-based detection of Enterococcus spp., coagulase-
negative Staphylococcus (CoNS), Staphylococcus aureus,
Streptococcus pneumoniae, Escherichia coli, Klebsiella
pneumoniae, Enterobacter cloacae, Proteus mirabilis,
Salmonella spp., Serratia marcescens, Acinetobacter bau-
mannii, Pseudomonas aeruginosa, Stenotrophomonas mal-
tophilia, Mycobacterium tuberculosis, Aspergillus spp.,
Candida spp. and Fusarium spp. were performed on an
ABI 7500 real-time PCR System (Applied Biosystems,
Foster City, CA, USA) instrument and quantified online
and at the endpoint with sequence detection system soft-
ware (version 2.0; Applied Biosystems) [4]. The primers
were checked for specificity in a BLAST search available
through the NCBI website (http://blast.ncbi.nlm.nih.gov/
Blast.cgi). A primer set for the haemochromatosis gene
was designed as an internal control for DNA extraction.
Resistance gene amplification by SYBR Green mono-
plex real-time PCR was performed in a 25-μL reaction
mixture containing 12.5 μL Platinum SYBR Green qPCR
SuperMix (Invitrogen, Carlsbad, CA, USA), 0.5 μM each
primer, and 5 μL purified DNA extracted from samples.
The real-time PCR conditions were as follows: 50 °C for
2 min and 95 °C for 10 min; 40 cycles of 95 °C for 15 s
and 60 °C for 60 s; and a melting curve step (from 68 to
95 °C in increments of 0.5 °C/s). The metallo-β-
lactamase amplification was performed by SYBR-based
multiplex real-time PCR.
The samples with discordant antimicrobial resist-
ance results between molecular and phenotypic ana-
lyses were submitted to a qPCR assay directly from of
the isolates strains. For methicillin-resistant Staphylo-
coccus strains with discordant results, we determined
the MIC for oxacillin with E test (fabricante) and the
diameter zone for cefoxitin with the disc diffusion
method following the Clinical and Laboratory Standards
Institute recommendations.
Data collection was performed using SSPS version 17.0
software (SPSS Inc., Chicago, IL, USA) and Microsoft
Office Excel 2010 (Microsoft, Redmond, WA, USA).
Results
Study population and patients characteristics
We identified 168 episodes of BSI, 81 episodes were in-
cluded in the study with BACTEC BC bottles and were
randomly available for molecular tests. Twelve episodes
with polymicrobial culture results were excluded and
our final data comprised 69 episodes of BSI from 64
patients.
Patients had a mean age of 7.8 years (range 0–
22 years), and 57.8 % were male. The underlying diseases
were: 20 % (13/64) acute lymphoid leukaemia; 19 %
(12/64) central nervous system tumour; 14 % (9/64)
acute myeloid leukaemia (AML); 9 % (6/64) non
Hodgkin’s lymphoma; 8 % (5/64) neuroblastoma; 6 %
(4/64) retinoblastoma; 5 % (3/64) osteosarcoma; 3 %
(2/64) Ewing’s sarcoma; 2 % (1/64) Wilms’ tumour; and
20 % (13/64) others less common childhood tumours.
Among the potential factors predisposing to BSI, a
central line catheter was present in 83 % (57/69), previous
antimicrobial therapy was administered in 54 % (37/69),
and neutropenia was present in 61 % (42/69). At onset of
clinical evaluation, the use of antimicrobial therapy was
observed in 85 % (59/69), sepsis was present in 68 %
(47/69), septic shock occurred in 4 % (4/69), and severe
sepsis in 3 % (2/69). Primary bacteraemia occurred in
91 % (63/69). Among secondary BSI caused by Gram-
positive bacteria, the skin was the source in 60 %, followed
by lungs and intestinal tract. In Gram-negative BSI, only
one pulmonary secondary episode of BSI was identified.
Sixteen patients died during the study period, and six
of these episodes occurred within 14 days and were re-
lated to BSI.
Phenotypic bacterial identification
Among 69 BSI episodes, 61 % (42/69) were caused by
Gram-positive bacteria, 32 % (22/69) by Gram-negative
bacteria, and 7 % (5/69) by fungi (Table 1). The three
major pathogens of BSI were: CoNS in 26 % (18/69),
followed by S. aureus in 13 % (9/69), and P. aeruginosa in
12 % (8/69). Five episodes were caused by fungi: Candida
tropicalis, Candida parapsilosis, Candida guillermondi,
Candida lusitaniae and Rhodotorula spp. (Table 1).
Comparison of molecular with phenotypic identification
methods
We performed phenotypic (automated) and molecular
(qPCR) method for 69 positive samples taken directly
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from BC bottles and compared both methods. The overall
concordance was 78.2 % for final species identification.
Among 42 samples positive for Gram-positive bacteria
detected by BC processing, 36 were positive by Gram-
postive 16 rDNA gene probe. Of these 36, 27 were iden-
tified at specie level by qPCR, 8 were identified by DNA
sequencing and 7 were not identified. Three samples
were discordant; in two of them the molecular method
was not able to identify any microorganism, and one BC
showed S. aureus and CoNS by qPCR. For 22 samples
with Gram-negative isolates identified by BC processing,
we observed a concordance of 81.8 % (18/22) with the
molecular method. In two of these samples, qPCR was
not able to identify the species, and in another two sam-
ples, the methods were discordant for species identifica-
tion (Table 2).
Methicillin resistance was detected in 88 % (24/27) of
the 27 Sthaphylococcus spp. samples identified by the
phenotypic method. The mecA gene was detected in 22/
24, corresponding to 91.6 % of concordance.
Two strains were identified as Enterococcus spp., and
one of them was resistant to vancomycin by the pheno-
typic method. There was 100 % of concordance with de-
tection of vanA by the molecular method.
The qPCR for extended spectrum β-lactamase (ESBL)
coding genes was concordant with the phenotypic
susceptibility profile test in 71.4 % (10/14) for
Enterobacteriaceae.
Among four discordant samples, two were E. coli and
had phenotypic detection of ESBL but no resistance gene
was detected by the molecular method. One sample
positive for E. coli with susceptibility to cephalosporins
showed blaCTX, which was not detected directly from
the isolated colony. The last discordant sample was posi-
tive for E. cloacae, with resistance to cephalosporins, but
no resistance gene was detected. We did not detect any
Enterobacteriaceae resistant to carbapenems by the
phenotypic method and by the molecular method for
blaKPC, blaIMP and blaVIM (Table 3).
Eight samples were positive for non-fermenting Gram-
negative bacteria by the phenotypic method, and qPCR
for resistance genes was performed in seven, we ex-
cluded the Achromobacter spp. sample.
Carbapenem resistance Pseudomonas aeruginosa was
phenotypically detected in four samples while two sam-
ples were negative for blaSPM gene. There was 50 % con-
cordance between both methods. One of these samples
had the blaSPM resistance gene detected when testing
the isolate strain (Table 3).
Five samples were positive for fungi, four Candida spp.
and one Rhodotorula spp., and the molecular method was
able to identify 80 % of the samples with Candida.
Antimicrobial therapy evaluation and death
Regarding antimicrobial therapy in Period 1, we ob-
served inadequacy in 43 %. All except one episode were
submitted to medical intervention at that time. In Period
2, the inadequacy remained in 12 % of episodes.
Death occurred in 16 % (11/69) of all the BSI episodes,
and six of these episodes occurred within 14 days and
were related to the BSI. The molecular method was con-
cordant with phenotypic identification of the agent in
50 % of these episodes. Therapy in Period 1 was inad-
equate in patients whose death was related to BSI (5/6).
In Period 2, three of them remained inadequate even
after intervention. In these cases, we were able to iden-
tify blaSPM in P. aeruginosa and vanA in Enterococcus
faecium by molecular test (Table 4).
Table 1 Rank order of bloodstream pathogens isolated from BSI
in paediatric cancer patients
Agents 69 (100 %)
Gram positive 42 (61)
CoNS 18 (26)
Staphylococcus aureus 9 (13)
Viridans group Streptococcus 6 (9)
Streptococcus spp. 3 (4)
Corynebacterium spp. 2 (3)
Enterococcus spp. 2 (3)
Other Gram positive 2 (3)
Gram negative 22 (32)
Pseudomonas. aeruginosa 8 (12)
Escherichia coli 6 (9)
Klebisiella pneumoniae 3 (4)
Enterobacter cloacae 2 (3)
Other Gram negative 3 (4)
Fungi 5 (7)
Candida tropicalis 1 (1)
Candida parapsilosis 1 (1)
Candida guillermondi 1 (1)
Candida lusitaniae 1 (1)
Rhodotorula spp. 1 (1)
CoNS Coagulase negative Staphylococci
Table 2 Discordant episodes between phenotypic and
molecular tests of isolates from BSI in paediatric cancer patients
Episode Phenotypic method Molecular method
24 Staphylococcus warneri Negative
29 Staphylococcus aureus Negative
47 Staphylococcus aureus CoNS
5 Escherichia coli Negative
59 Pseudomonas aeruginosa Negative
68 Burkholderia cepacia CoNS/Ralstonia pickettii
CoNS Coagulase negative Staphylococci
Carlesse et al. BMC Infectious Diseases  (2016) 16:462 Page 4 of 8
Discussion
The strategy of using empirical antibiotic therapy has
greatly influenced the outcome of fever in paediatric
cancer patients. Unfortunately, BC can identify patho-
gens in only 40 % of children with fever and can take
>24 h to yield a report [3].
We evaluated 69 episodes of BSI from 64 patients. The
predominant underlying disease was haematological ma-
lignancy, this group of patients constitute the group of
major risk for development of invasive bacterial infec-
tions, due to aggressive chemotherapy that results in
long periods of neutropenia [9].
In our study, more than half of our patients were neu-
tropenic, which has been recognised as an important
risk factor for life-threatening infection since the 1960s
when Bodey et al. identified a strong inverse correlation
between the degree of neutropenia and the probability of
infection [10–12].
We found a predominance of Gram-positive bacteria
followed by Gram-negative bacteria, and fungi. Although
we only studied a small sample, our results agree with
our historic series and with the literature [7, 9, 13].
Among Gram-positive bacteria, CoNS was the main
agent found, followed by Staphylococcus aureus which
Table 3 Resistance genes identified by molecular method and antimicrobial susceptibility for Gram-negative BSI
Episode Phenotypic method Resistance gene Cefepime susceptibility Meropenem susceptibility
1 Klebsiella pneumoniae Negative Susceptible Susceptible
2 Acinetobacter baumannii Negative Susceptible Susceptible
5 Escherichia coli Negative Resistant Susceptible
6 Escherichia coli Negative Susceptible Susceptible
8 Serratia marcescens Negative Susceptible Susceptible
11 Enterobacter cloacae Negative Susceptible Susceptible
16 K. pneumoniae Negative Susceptible Susceptible
17 Klebsiella oxytoca Negative Susceptible Susceptible
18 Achromobacter spp. Negative NT NT
21 Escherichia coli Negative Susceptible Susceptible
25 Enterobacter cloacae Negative Resistant Susceptible
32 Pseudomonas putida Negative NT NT
38 Pseudomonas aeruginosa Negative Resistant Resistant
41 Klebsiella pneumoniae blaTEM blaCTX Resistant Susceptible
43 Escherichia coli bla CTX Susceptible Susceptible
46 Pseudomonas aeruginosa bla SPM Resistant Resistant
49 Escherichia coli Negative Resistant Susceptible
50 Pseudomonas aeruginosa Negative Resistant Susceptible
54 Citrobacter freundii bla CTX Resistant Susceptible
59 Pseudomonas aeruginosa Negative Resistant Resistant
65 Escherichia coli Negative Susceptible Susceptible
68 Burkholderia cepacia Negative NT Resistant
NT not tested
Table 4 Phenotypic susceptibility, molecular tests and antimicrobial therapy of patients with death related to BSI
Episode Underlying
disease
Method Phenotypic susceptibility Resistance
gene
Antimicrobial therapy
Phenotypic Molecular Cefepime Meropenen Vancomycin Period 1 Period 2
5 AML E. coli Negative Resistant Susceptible NA Neg Modified Adequate
31 Other C. tropicalis Candida spp. NA NA NA NA Adequate Adequate
46 Wilms’ tumour P. aeruginosa P. aeruginosa Resistant Resistant NA blaSPM Modified Inadequate
56 ALL C. lusitanae Negative NA NA NA NA Modified Inadequate
58 ALL P. aeruginosa Negative Resistant Resistant NA Neg Modified Adequate
69 RMS E. faecium Enterococcus spp. NA NA Resistant vanA Modified Inadequate
ALL acute lymphoid leukaemia, RMS Rhabdomyosarcoma, Neg negative, NA not applicable
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agrees with most epidemiological studies in this setting
and is related with catheter implantation [14, 15].
Complications of S. aureus infection have been re-
ported in paediatric cancer patients in 10–18 % of all in-
fections and up to 33 % of cases of bacteraemia [16]. In
our study, the majority of the patients with S. aureus in-
fection had central venous catheter (CVC) (66 %) and
primary bacteraemia. Mortality from S. aureus in paedi-
atric oncologic setting is reported at 2.3 % [16]. No pa-
tient with S. aureus BSI died in our study.
Viridans group Streptococcus was the third in rank
order of BSI in our patients. Infections due to viri-
dans group Streptococcus have been seen especially in
patients with AML, corresponding to ~25 % of all
BSIs in these patients [17]. The mortality rate is high
as 20 % [18]. In institutions with a high prevalence of
this agent, the initial empirical antibiotic therapy in-
cludes vancomycin [19].
Among Gram-negative isolates, Enterobacteriaceae
were predominant, with E. coli followed by K. pneumo-
niae as the main agents.
Pseudomonas aeruginosa was the main agent among
non-fermenting bacteria and despite improvement in
recent years, the prognosis of infection due this agent in
this patient population remains poor, with case fatality
rates exceeding 20 % [20]. Our institution has been
treating patients with FN according to risk stratification
for life-threatening infections; patients considered low
risk receive moxifloxacin as outpatients, and high-risk
patients receive cefepime as inpatients [7, 21].
We compared 69 positive BC episodes using pheno-
typic and molecular methods. The overall concordance
was 78.2 % for final species identification, which is simi-
lar to a study conducted by Varani et al. in 2009 who
found 79.2 % concordance between the two methods
[22]. Comparing the two methods only for Gram-
positive pathogens, the final species concordance identi-
fication was 89.6 %.
Recent studies have observed an increase in methicillin-
resistant Staphylococcus infections, especially in patients
with haematological malignancies; 70–80 % among CoNS
and 25–30 % among S. aureus [23]. We detected 78 %
methicillin resistance in BSI caused by S. aureus. The mo-
lecular method was able to detect the mecA gene in 93 %
of these cases. Two samples were discordant, and when
the molecular method was applied directly to the isolated
colonies, it was concordant with the phenotypic method.
Samples in which the phenotypic method shows
methicillin resistance and the mecA gene is not found
must be evaluated for mecC, and if this is present,
patients must be managed as if they have methicillin-
resistant S. aureus [24].
Resistance to vancomycin among enterococci has
emerged as a general problem and is now found in
patients with FN [25]. We found that 5 % of BSIs were
due to Enterococcus spp., and 50 % were VRE. In our
study we had one patient with VRE BSI infection who
died 4 days after he had a positive BC and 1 day after
the final result of BC emerged, which reflects the im-
portance of early diagnosis. The molecular method was
concordant in 100 % of the cases. Early identification of
VRE is important beyond the therapeutic approach be-
cause this contributes to infection control procedures to
avoid the spread of these microorganisms.
Three of our four P. aeruginosa isolates were resistant
to carbapenems by the phenotypic method, which
agreed with our molecular method in 50 % of cases. In
the two discordant samples, we tested for the presence
of the MBL genes directly from the isolated colonies;
one of which was positive for blaSPM and one negative
for MBL genes. This suggests that another mechanism
was responsible for carbapenem resistance, such as porin
loss or efflux systems.
Even though the rate of infection with carbapenem-
resistant Acinetobacter spp. is increasing, we found only
one infection due to A. baumannii and it was suscep-
tible to cefepime and carbapenems.
Enterobacteriaceae were predominant among Gram-
negative isolates, and the main agent was E. coli,
followed by K. pneumoniae, with a high concordance in
final species identification between the two methods.
The literature shows an incidence of ESBL among
E. coli varying from 12.6 to 48.3 % [26, 27]. In our
study, 60 % of E. coli were ESBL producers, showing
78.5 % concordance with the molecular method.
Three samples were discordant. Two of those had a
phenotypic profile of ESBL and no resistance genes
were detected. The other sample was susceptible to
cephalosporins, and we found blaCTX-M, which was
not confirmed in an additional test performed directly
on the isolated colony. The patient received treatment
with cefepime and had a good outcome.
Regarding fungal infection, our molecular method was
able to identify yeasts, with the exception of one episode
of C. lusitaniae that was responsible for one death. This
is an uncommon species of Candida in these patients
and it is important to note that it can be resistant to
amphotericin B [28].
The impact of early appropriate antibiotic therapy on
patient survival has been demonstrated in previous stud-
ies [1, 12, 29, 30]. In our study, we showed that only one
of six patients who died within 14 days after BSI had ad-
equate initial empirical therapy. Therapy was modified
in five cases based on Gram staining of the positive BC
(Period 1) and after the final results, three treatments
remained inadequate. The molecular method was able to
identify the microorganism and resistance gene in two of
these three cases.
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Early identification of the causative organism and re-
sistance genes such as vanA for enterococci and MBL
for P. aeruginosa is crucial for adequate antimicrobial
therapy, especially in paediatric neutropenic patients.
Our empirical treatment approach does not take into ac-
count the resistant microorganisms shown in our study.
A limitation of the method is that PCR is so sensitive
that we could not exclude the risk of false positive from
skin contamination during blood culture collection par-
ticularly for CoSN. Other molecular mechanisms of re-
sistance could be added since our “in house” multiplex is
done in an open qPCR plataform.
Conclusions
The addition of molecular tests, including qPCR, for
identification of pathogens and detection of antimicro-
bial resistance genes to the classical phenotypic tests in
BSI is particularly relevant in paediatric cancer patients.
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